Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation and Depletion: 2021-2024

Historic Depreciation and Depletion for Compass Therapeutics (CMPX) over the last 4 years, with Dec 2024 value amounting to $600,000.

  • Compass Therapeutics' Depreciation and Depletion fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 42.86%. This contributed to the annual value of $600,000 for FY2024, which is 14.29% down from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Depreciation and Depletion is $600,000, which was down 14.29% from $700,000 recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Depreciation and Depletion ranged from a high of $800,000 in FY2022 and a low of $600,000 during FY2021.
  • Over the past 3 years, Compass Therapeutics' median Depreciation and Depletion value was $700,000 (recorded in 2023), while the average stood at $700,000.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 33.33% in 2022, then dropped by 14.29% in 2024.
  • Compass Therapeutics' Depreciation and Depletion (Yearly) stood at $600,000 in 2021, then soared by 33.33% to $800,000 in 2022, then dropped by 12.50% to $700,000 in 2023, then dropped by 14.29% to $600,000 in 2024.